Our Pipelines
Novel Biologics
We are developing innovative proprietary platforms and pre-clinical programs for the novel drugs and with an immediate basis MeTagic will be used for 2 novel drugs that we are currently working on.
Biosimilars
We are working towards our goal of having a niche biosimilar portfolio in the ASEAN region for monoclonal antibodies, to address the unmet needs of accessibility